🔗 Share this article

Given that the United States continues making historic revisions to its vaccine schedules, a particular individual has emerged in a surprising turn: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by questioning Covid shots throughout the pandemic and has concentrated on potential deaths after Covid vaccination in her brief position at the FDA.

Planned Overhauls to Pediatric Immunization Program

Public health authorities were set to unveil radical changes to the pediatric vaccine schedule in December, aligning the US with the Danish national calendar, sources say – a substantial departure that would put the US at odds with many the global community with no evidence for public health gain. The announcement has been delayed until the next year.

In place of the director of the vaccine center, Høeg is listed to speak at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this calendar year.

A New Direction at the FDA

This interim role could signify a closer partnership between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing some pediatric vaccine recommendations in the US so as to align more in line with Denmark's approach, a country with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – traditionally the responsibility of Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Background

The appointee has no apparent track record in pharmaceutical research, oversight or management, which has been typical for previous leaders of the CBER. She has worked at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a major agency. She is not an expert in industry regulation.”

Previous heads of CBER would “grasp legal statutes and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she lacks the type of experience that prior appointees who ran the center have had.”

This division has an vast workload at the FDA, Woodcock pointed out.

“The public just focuses on the novel medication approvals, but the generic drug division authorizes numerous off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one must be looked after,” she explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative component to the position, which manages in excess of 5,000 personnel. “It’s a huge leadership role, if you do it right,” the former official added.

Response and Disputed Initiatives

Regarding inquiries about Høeg’s fitness for the role and whether this appointment represents increased cooperation among agency officials on vaccines, a spokesperson stated that the “concerns rely on flawed premises”.

“Her experience matches the functions of her job,” the spokesperson explained, pointing to the months Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg inherits the agency head's new expedited review system, a contentious rapid medication authorization process that apparently concerned her former heads. “How are these medications being picked for this voucher program? Who is making the calls?” Dr. Howard asked. “There’s a lot of confidentiality happening at the agency right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards less stringent oversight of all drugs, except for immunizations.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a clearer, if problematic, history, some experts have noted. She published a analysis using unverified crowd-sourced reports to assess the frequency of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the new government featured revising regulations for recently developed shots and ending “non-essential” immunizations, she said following the vote on a audio program. At the agency, Høeg has reportedly floated the idea of excluding young men from obtaining Covid vaccinations.

“She is an all-around ideologue who begins with her beliefs and reverse-engineers to fit the science in a extremely deceptive, untruthful manner,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|